nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ABCC1—Etoposide—brain cancer	0.102	0.148	CbGbCtD
Vemurafenib—CYP2D6—Lomustine—brain cancer	0.0956	0.139	CbGbCtD
Vemurafenib—CYP1A2—Carmustine—brain cancer	0.0945	0.137	CbGbCtD
Vemurafenib—ABCG2—Carboplatin—brain cancer	0.081	0.118	CbGbCtD
Vemurafenib—CYP2D6—Hydroxyurea—brain cancer	0.0724	0.105	CbGbCtD
Vemurafenib—CYP3A4—Temozolomide—brain cancer	0.0715	0.104	CbGbCtD
Vemurafenib—ABCG2—Etoposide—brain cancer	0.068	0.0988	CbGbCtD
Vemurafenib—CYP3A4—Lomustine—brain cancer	0.0608	0.0883	CbGbCtD
Vemurafenib—CYP1A2—Etoposide—brain cancer	0.028	0.0407	CbGbCtD
Vemurafenib—CYP3A4—Etoposide—brain cancer	0.0147	0.0213	CbGbCtD
Vemurafenib—Etoricoxib—CYP2C9—brain cancer	0.00595	1	CrCbGaD
Vemurafenib—Hepatotoxicity—Lomustine—brain cancer	0.00444	0.0348	CcSEcCtD
Vemurafenib—VIIth nerve paralysis—Carmustine—brain cancer	0.00332	0.026	CcSEcCtD
Vemurafenib—Neoplasm—Lomustine—brain cancer	0.0031	0.0243	CcSEcCtD
Vemurafenib—RAF1—hindbrain—brain cancer	0.0027	0.0885	CbGeAlD
Vemurafenib—Neoplasm malignant—Procarbazine—brain cancer	0.00255	0.02	CcSEcCtD
Vemurafenib—Hepatotoxicity—Hydroxyurea—brain cancer	0.00218	0.0171	CcSEcCtD
Vemurafenib—Cyst—Carmustine—brain cancer	0.00204	0.016	CcSEcCtD
Vemurafenib—Photosensitivity—Procarbazine—brain cancer	0.0018	0.0141	CcSEcCtD
Vemurafenib—Hepatotoxicity—Carmustine—brain cancer	0.00176	0.0138	CcSEcCtD
Vemurafenib—Hepatotoxicity—Temozolomide—brain cancer	0.0017	0.0134	CcSEcCtD
Vemurafenib—BRAF—pituitary gland—brain cancer	0.00168	0.055	CbGeAlD
Vemurafenib—Rigors—Temozolomide—brain cancer	0.00161	0.0126	CcSEcCtD
Vemurafenib—Gamma-glutamyltransferase increased—Temozolomide—brain cancer	0.0016	0.0125	CcSEcCtD
Vemurafenib—RAF1—brainstem—brain cancer	0.00155	0.0507	CbGeAlD
Vemurafenib—Rash maculo-papular—Hydroxyurea—brain cancer	0.00153	0.012	CcSEcCtD
Vemurafenib—Neoplasm—Hydroxyurea—brain cancer	0.00152	0.0119	CcSEcCtD
Vemurafenib—Alopecia—Lomustine—brain cancer	0.00152	0.0119	CcSEcCtD
Vemurafenib—BRAF—midbrain—brain cancer	0.00148	0.0485	CbGeAlD
Vemurafenib—Toxic epidermal necrolysis—Procarbazine—brain cancer	0.00142	0.0111	CcSEcCtD
Vemurafenib—Infection—Carboplatin—brain cancer	0.00139	0.0109	CcSEcCtD
Vemurafenib—RAF1—telencephalon—brain cancer	0.00137	0.045	CbGeAlD
Vemurafenib—Hepatotoxicity—Etoposide—brain cancer	0.00136	0.0107	CcSEcCtD
Vemurafenib—Eosinophilia—Procarbazine—brain cancer	0.00135	0.0106	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Temozolomide—brain cancer	0.00133	0.0104	CcSEcCtD
Vemurafenib—Rigors—Etoposide—brain cancer	0.00129	0.0101	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Procarbazine—brain cancer	0.00125	0.00976	CcSEcCtD
Vemurafenib—Neoplasm—Carmustine—brain cancer	0.00123	0.00965	CcSEcCtD
Vemurafenib—Infection—Lomustine—brain cancer	0.00122	0.00952	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Procarbazine—brain cancer	0.00119	0.00935	CcSEcCtD
Vemurafenib—Neoplasm—Temozolomide—brain cancer	0.00119	0.00932	CcSEcCtD
Vemurafenib—RAF1—gonad—brain cancer	0.00114	0.0376	CbGeAlD
Vemurafenib—BRAF—cerebellum—brain cancer	0.00114	0.0375	CbGeAlD
Vemurafenib—RAF1—pituitary gland—brain cancer	0.00112	0.0366	CbGeAlD
Vemurafenib—Body temperature increased—Carboplatin—brain cancer	0.00111	0.00866	CcSEcCtD
Vemurafenib—RAF1—medulla oblongata—brain cancer	0.00108	0.0354	CbGeAlD
Vemurafenib—Decreased appetite—Lomustine—brain cancer	0.00106	0.00833	CcSEcCtD
Vemurafenib—RAF1—midbrain—brain cancer	0.000985	0.0323	CbGeAlD
Vemurafenib—Chills—Procarbazine—brain cancer	0.000981	0.00768	CcSEcCtD
Vemurafenib—Body temperature increased—Lomustine—brain cancer	0.000967	0.00757	CcSEcCtD
Vemurafenib—Alopecia—Procarbazine—brain cancer	0.000966	0.00757	CcSEcCtD
Vemurafenib—RAF1—spinal cord—brain cancer	0.000961	0.0315	CbGeAlD
Vemurafenib—Rash maculo-papular—Etoposide—brain cancer	0.000957	0.0075	CcSEcCtD
Vemurafenib—Infestation—Hydroxyurea—brain cancer	0.000943	0.00738	CcSEcCtD
Vemurafenib—Infestation NOS—Hydroxyurea—brain cancer	0.000943	0.00738	CcSEcCtD
Vemurafenib—BRAF—brain—brain cancer	0.000929	0.0305	CbGeAlD
Vemurafenib—Neuropathy peripheral—Hydroxyurea—brain cancer	0.000924	0.00724	CcSEcCtD
Vemurafenib—Dry skin—Temozolomide—brain cancer	0.000876	0.00686	CcSEcCtD
Vemurafenib—RAF1—endocrine gland—brain cancer	0.000865	0.0284	CbGeAlD
Vemurafenib—Toxic epidermal necrolysis—Temozolomide—brain cancer	0.00086	0.00674	CcSEcCtD
Vemurafenib—RAF1—head—brain cancer	0.000854	0.028	CbGeAlD
Vemurafenib—Cough—Procarbazine—brain cancer	0.000831	0.0065	CcSEcCtD
Vemurafenib—Myalgia—Procarbazine—brain cancer	0.00081	0.00635	CcSEcCtD
Vemurafenib—Arthralgia—Procarbazine—brain cancer	0.00081	0.00635	CcSEcCtD
Vemurafenib—RAF1—central nervous system—brain cancer	0.00078	0.0256	CbGeAlD
Vemurafenib—Vomiting—Lomustine—brain cancer	0.000778	0.00609	CcSEcCtD
Vemurafenib—Infection—Procarbazine—brain cancer	0.000772	0.00604	CcSEcCtD
Vemurafenib—Angiopathy—Hydroxyurea—brain cancer	0.000768	0.00601	CcSEcCtD
Vemurafenib—CYP2D6—hindbrain—brain cancer	0.000765	0.0251	CbGeAlD
Vemurafenib—RAF1—cerebellum—brain cancer	0.000762	0.025	CbGeAlD
Vemurafenib—Chills—Hydroxyurea—brain cancer	0.000759	0.00595	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Temozolomide—brain cancer	0.000754	0.0059	CcSEcCtD
Vemurafenib—Alopecia—Hydroxyurea—brain cancer	0.000748	0.00586	CcSEcCtD
Vemurafenib—Weight decreased—Temozolomide—brain cancer	0.000747	0.00585	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Carmustine—brain cancer	0.000747	0.00585	CcSEcCtD
Vemurafenib—Erythema—Hydroxyurea—brain cancer	0.000737	0.00577	CcSEcCtD
Vemurafenib—Infestation NOS—Temozolomide—brain cancer	0.000736	0.00577	CcSEcCtD
Vemurafenib—Infestation—Temozolomide—brain cancer	0.000736	0.00577	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.00073	0.00572	CcSEcCtD
Vemurafenib—Nausea—Lomustine—brain cancer	0.000727	0.00569	CcSEcCtD
Vemurafenib—Hypotension—Procarbazine—brain cancer	0.000726	0.00568	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Temozolomide—brain cancer	0.000722	0.00565	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000708	0.00554	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Etoposide—brain cancer	0.000689	0.00539	CcSEcCtD
Vemurafenib—ABCC1—telencephalon—brain cancer	0.000685	0.0225	CbGeAlD
Vemurafenib—Decreased appetite—Procarbazine—brain cancer	0.000675	0.00529	CcSEcCtD
Vemurafenib—Oedema peripheral—Carmustine—brain cancer	0.000674	0.00528	CcSEcCtD
Vemurafenib—Connective tissue disorder—Carmustine—brain cancer	0.000672	0.00526	CcSEcCtD
Vemurafenib—Fatigue—Procarbazine—brain cancer	0.00067	0.00525	CcSEcCtD
Vemurafenib—Constipation—Procarbazine—brain cancer	0.000664	0.0052	CcSEcCtD
Vemurafenib—ORM1—spinal cord—brain cancer	0.000663	0.0218	CbGeAlD
Vemurafenib—Oedema peripheral—Temozolomide—brain cancer	0.000651	0.0051	CcSEcCtD
Vemurafenib—Connective tissue disorder—Temozolomide—brain cancer	0.00065	0.00509	CcSEcCtD
Vemurafenib—Eye disorder—Carmustine—brain cancer	0.000639	0.00501	CcSEcCtD
Vemurafenib—Erythema multiforme—Temozolomide—brain cancer	0.000625	0.0049	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000623	0.00488	CcSEcCtD
Vemurafenib—RAF1—brain—brain cancer	0.000619	0.0203	CbGeAlD
Vemurafenib—Eye disorder—Temozolomide—brain cancer	0.000618	0.00484	CcSEcCtD
Vemurafenib—Body temperature increased—Procarbazine—brain cancer	0.000614	0.00481	CcSEcCtD
Vemurafenib—Cardiac disorder—Temozolomide—brain cancer	0.000614	0.0048	CcSEcCtD
Vemurafenib—Alopecia—Carmustine—brain cancer	0.000604	0.00473	CcSEcCtD
Vemurafenib—Angiopathy—Temozolomide—brain cancer	0.0006	0.0047	CcSEcCtD
Vemurafenib—ORM1—endocrine gland—brain cancer	0.000597	0.0196	CbGeAlD
Vemurafenib—Infection—Hydroxyurea—brain cancer	0.000597	0.00468	CcSEcCtD
Vemurafenib—Mediastinal disorder—Temozolomide—brain cancer	0.000596	0.00467	CcSEcCtD
Vemurafenib—Erythema—Carmustine—brain cancer	0.000595	0.00466	CcSEcCtD
Vemurafenib—Malnutrition—Carmustine—brain cancer	0.000595	0.00466	CcSEcCtD
Vemurafenib—Chills—Temozolomide—brain cancer	0.000593	0.00465	CcSEcCtD
Vemurafenib—Nervous system disorder—Hydroxyurea—brain cancer	0.00059	0.00462	CcSEcCtD
Vemurafenib—Infestation—Etoposide—brain cancer	0.000589	0.00461	CcSEcCtD
Vemurafenib—Infestation NOS—Etoposide—brain cancer	0.000589	0.00461	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000584	0.00458	CcSEcCtD
Vemurafenib—Alopecia—Temozolomide—brain cancer	0.000584	0.00457	CcSEcCtD
Vemurafenib—Skin disorder—Hydroxyurea—brain cancer	0.000584	0.00457	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Etoposide—brain cancer	0.000578	0.00452	CcSEcCtD
Vemurafenib—Back pain—Carmustine—brain cancer	0.000576	0.00451	CcSEcCtD
Vemurafenib—Erythema—Temozolomide—brain cancer	0.000575	0.00451	CcSEcCtD
Vemurafenib—Malnutrition—Temozolomide—brain cancer	0.000575	0.00451	CcSEcCtD
Vemurafenib—Hypersensitivity—Procarbazine—brain cancer	0.000572	0.00448	CcSEcCtD
Vemurafenib—ABCG2—telencephalon—brain cancer	0.000567	0.0186	CbGeAlD
Vemurafenib—Dysgeusia—Temozolomide—brain cancer	0.000564	0.00441	CcSEcCtD
Vemurafenib—ABCC1—pituitary gland—brain cancer	0.000558	0.0183	CbGeAlD
Vemurafenib—Asthenia—Procarbazine—brain cancer	0.000557	0.00436	CcSEcCtD
Vemurafenib—Back pain—Temozolomide—brain cancer	0.000557	0.00436	CcSEcCtD
Vemurafenib—Pruritus—Procarbazine—brain cancer	0.00055	0.0043	CcSEcCtD
Vemurafenib—ORM1—central nervous system—brain cancer	0.000538	0.0177	CbGeAlD
Vemurafenib—Diarrhoea—Procarbazine—brain cancer	0.000531	0.00416	CcSEcCtD
Vemurafenib—Decreased appetite—Hydroxyurea—brain cancer	0.000523	0.00409	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000519	0.00406	CcSEcCtD
Vemurafenib—Fatigue—Hydroxyurea—brain cancer	0.000518	0.00406	CcSEcCtD
Vemurafenib—Constipation—Hydroxyurea—brain cancer	0.000514	0.00403	CcSEcCtD
Vemurafenib—Dizziness—Procarbazine—brain cancer	0.000514	0.00402	CcSEcCtD
Vemurafenib—Myalgia—Carmustine—brain cancer	0.000507	0.00397	CcSEcCtD
Vemurafenib—Cough—Temozolomide—brain cancer	0.000502	0.00393	CcSEcCtD
Vemurafenib—Erythema multiforme—Etoposide—brain cancer	0.0005	0.00392	CcSEcCtD
Vemurafenib—Eye disorder—Etoposide—brain cancer	0.000494	0.00387	CcSEcCtD
Vemurafenib—Vomiting—Procarbazine—brain cancer	0.000494	0.00387	CcSEcCtD
Vemurafenib—Cardiac disorder—Etoposide—brain cancer	0.000491	0.00384	CcSEcCtD
Vemurafenib—Arthralgia—Temozolomide—brain cancer	0.00049	0.00384	CcSEcCtD
Vemurafenib—Myalgia—Temozolomide—brain cancer	0.00049	0.00384	CcSEcCtD
Vemurafenib—Rash—Procarbazine—brain cancer	0.00049	0.00384	CcSEcCtD
Vemurafenib—Dermatitis—Procarbazine—brain cancer	0.000489	0.00383	CcSEcCtD
Vemurafenib—Headache—Procarbazine—brain cancer	0.000487	0.00381	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000487	0.00381	CcSEcCtD
Vemurafenib—Infection—Carmustine—brain cancer	0.000483	0.00378	CcSEcCtD
Vemurafenib—Angiopathy—Etoposide—brain cancer	0.00048	0.00376	CcSEcCtD
Vemurafenib—Mediastinal disorder—Etoposide—brain cancer	0.000477	0.00373	CcSEcCtD
Vemurafenib—Body temperature increased—Hydroxyurea—brain cancer	0.000475	0.00372	CcSEcCtD
Vemurafenib—Chills—Etoposide—brain cancer	0.000475	0.00372	CcSEcCtD
Vemurafenib—Anaphylactic shock—Temozolomide—brain cancer	0.00047	0.00368	CcSEcCtD
Vemurafenib—Alopecia—Etoposide—brain cancer	0.000467	0.00366	CcSEcCtD
Vemurafenib—Infection—Temozolomide—brain cancer	0.000467	0.00365	CcSEcCtD
Vemurafenib—ABCG2—pituitary gland—brain cancer	0.000462	0.0152	CbGeAlD
Vemurafenib—Nausea—Procarbazine—brain cancer	0.000461	0.00361	CcSEcCtD
Vemurafenib—Nervous system disorder—Temozolomide—brain cancer	0.000461	0.00361	CcSEcCtD
Vemurafenib—Skin disorder—Temozolomide—brain cancer	0.000456	0.00357	CcSEcCtD
Vemurafenib—Hypotension—Carmustine—brain cancer	0.000454	0.00356	CcSEcCtD
Vemurafenib—Dysgeusia—Etoposide—brain cancer	0.000451	0.00353	CcSEcCtD
Vemurafenib—ABCG2—medulla oblongata—brain cancer	0.000446	0.0146	CbGeAlD
Vemurafenib—Back pain—Etoposide—brain cancer	0.000445	0.00349	CcSEcCtD
Vemurafenib—Hypersensitivity—Hydroxyurea—brain cancer	0.000443	0.00347	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000443	0.00347	CcSEcCtD
Vemurafenib—CYP2D6—brainstem—brain cancer	0.000438	0.0144	CbGeAlD
Vemurafenib—Asthenia—Hydroxyurea—brain cancer	0.000431	0.00338	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000428	0.00335	CcSEcCtD
Vemurafenib—Decreased appetite—Carmustine—brain cancer	0.000422	0.00331	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Carmustine—brain cancer	0.00042	0.00329	CcSEcCtD
Vemurafenib—Constipation—Carmustine—brain cancer	0.000416	0.00325	CcSEcCtD
Vemurafenib—Diarrhoea—Hydroxyurea—brain cancer	0.000411	0.00322	CcSEcCtD
Vemurafenib—Decreased appetite—Temozolomide—brain cancer	0.000408	0.0032	CcSEcCtD
Vemurafenib—ABCG2—midbrain—brain cancer	0.000407	0.0134	CbGeAlD
Vemurafenib—Gastrointestinal disorder—Temozolomide—brain cancer	0.000405	0.00318	CcSEcCtD
Vemurafenib—Fatigue—Temozolomide—brain cancer	0.000405	0.00317	CcSEcCtD
Vemurafenib—Cough—Etoposide—brain cancer	0.000402	0.00315	CcSEcCtD
Vemurafenib—Constipation—Temozolomide—brain cancer	0.000402	0.00315	CcSEcCtD
Vemurafenib—Dizziness—Hydroxyurea—brain cancer	0.000398	0.00311	CcSEcCtD
Vemurafenib—ABCG2—spinal cord—brain cancer	0.000398	0.013	CbGeAlD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000389	0.00305	CcSEcCtD
Vemurafenib—CYP2D6—telencephalon—brain cancer	0.000389	0.0128	CbGeAlD
Vemurafenib—Body temperature increased—Carmustine—brain cancer	0.000384	0.00301	CcSEcCtD
Vemurafenib—Vomiting—Hydroxyurea—brain cancer	0.000382	0.00299	CcSEcCtD
Vemurafenib—ABCC1—cerebellum—brain cancer	0.000381	0.0125	CbGeAlD
Vemurafenib—Rash—Hydroxyurea—brain cancer	0.000379	0.00297	CcSEcCtD
Vemurafenib—Dermatitis—Hydroxyurea—brain cancer	0.000379	0.00297	CcSEcCtD
Vemurafenib—Headache—Hydroxyurea—brain cancer	0.000377	0.00295	CcSEcCtD
Vemurafenib—Anaphylactic shock—Etoposide—brain cancer	0.000376	0.00294	CcSEcCtD
Vemurafenib—ALB—brain—brain cancer	0.000375	0.0123	CbGeAlD
Vemurafenib—Infection—Etoposide—brain cancer	0.000373	0.00292	CcSEcCtD
Vemurafenib—Body temperature increased—Temozolomide—brain cancer	0.000371	0.00291	CcSEcCtD
Vemurafenib—Skin disorder—Etoposide—brain cancer	0.000365	0.00286	CcSEcCtD
Vemurafenib—Hypersensitivity—Carmustine—brain cancer	0.000358	0.0028	CcSEcCtD
Vemurafenib—Nausea—Hydroxyurea—brain cancer	0.000357	0.0028	CcSEcCtD
Vemurafenib—Hypotension—Etoposide—brain cancer	0.000351	0.00275	CcSEcCtD
Vemurafenib—Asthenia—Carmustine—brain cancer	0.000349	0.00273	CcSEcCtD
Vemurafenib—Hypersensitivity—Temozolomide—brain cancer	0.000346	0.00271	CcSEcCtD
Vemurafenib—CYP1A2—endocrine gland—brain cancer	0.000344	0.0113	CbGeAlD
Vemurafenib—Asthenia—Temozolomide—brain cancer	0.000337	0.00264	CcSEcCtD
Vemurafenib—Diarrhoea—Carmustine—brain cancer	0.000333	0.0026	CcSEcCtD
Vemurafenib—Pruritus—Temozolomide—brain cancer	0.000332	0.0026	CcSEcCtD
Vemurafenib—Decreased appetite—Etoposide—brain cancer	0.000327	0.00256	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Etoposide—brain cancer	0.000324	0.00254	CcSEcCtD
Vemurafenib—Fatigue—Etoposide—brain cancer	0.000324	0.00254	CcSEcCtD
Vemurafenib—Dizziness—Carmustine—brain cancer	0.000321	0.00252	CcSEcCtD
Vemurafenib—Constipation—Etoposide—brain cancer	0.000321	0.00252	CcSEcCtD
Vemurafenib—Diarrhoea—Temozolomide—brain cancer	0.000321	0.00252	CcSEcCtD
Vemurafenib—ABCG2—cerebellum—brain cancer	0.000315	0.0103	CbGeAlD
Vemurafenib—Dizziness—Temozolomide—brain cancer	0.000311	0.00243	CcSEcCtD
Vemurafenib—ABCC1—brain—brain cancer	0.000309	0.0101	CbGeAlD
Vemurafenib—Vomiting—Carmustine—brain cancer	0.000309	0.00242	CcSEcCtD
Vemurafenib—Rash—Carmustine—brain cancer	0.000306	0.0024	CcSEcCtD
Vemurafenib—Dermatitis—Carmustine—brain cancer	0.000306	0.0024	CcSEcCtD
Vemurafenib—Headache—Carmustine—brain cancer	0.000304	0.00238	CcSEcCtD
Vemurafenib—Vomiting—Temozolomide—brain cancer	0.000299	0.00234	CcSEcCtD
Vemurafenib—Body temperature increased—Etoposide—brain cancer	0.000297	0.00233	CcSEcCtD
Vemurafenib—Rash—Temozolomide—brain cancer	0.000296	0.00232	CcSEcCtD
Vemurafenib—Dermatitis—Temozolomide—brain cancer	0.000296	0.00232	CcSEcCtD
Vemurafenib—Headache—Temozolomide—brain cancer	0.000294	0.0023	CcSEcCtD
Vemurafenib—Nausea—Carmustine—brain cancer	0.000289	0.00226	CcSEcCtD
Vemurafenib—Nausea—Temozolomide—brain cancer	0.000279	0.00218	CcSEcCtD
Vemurafenib—Hypersensitivity—Etoposide—brain cancer	0.000277	0.00217	CcSEcCtD
Vemurafenib—Asthenia—Etoposide—brain cancer	0.00027	0.00211	CcSEcCtD
Vemurafenib—Pruritus—Etoposide—brain cancer	0.000266	0.00208	CcSEcCtD
Vemurafenib—Diarrhoea—Etoposide—brain cancer	0.000257	0.00201	CcSEcCtD
Vemurafenib—ABCG2—brain—brain cancer	0.000256	0.0084	CbGeAlD
Vemurafenib—CYP3A4—endocrine gland—brain cancer	0.000249	0.00818	CbGeAlD
Vemurafenib—Dizziness—Etoposide—brain cancer	0.000249	0.00195	CcSEcCtD
Vemurafenib—CYP2D6—endocrine gland—brain cancer	0.000245	0.00805	CbGeAlD
Vemurafenib—CYP2D6—head—brain cancer	0.000242	0.00795	CbGeAlD
Vemurafenib—Vomiting—Etoposide—brain cancer	0.000239	0.00187	CcSEcCtD
Vemurafenib—Rash—Etoposide—brain cancer	0.000237	0.00186	CcSEcCtD
Vemurafenib—Dermatitis—Etoposide—brain cancer	0.000237	0.00185	CcSEcCtD
Vemurafenib—Headache—Etoposide—brain cancer	0.000235	0.00184	CcSEcCtD
Vemurafenib—CYP3A4—central nervous system—brain cancer	0.000225	0.00737	CbGeAlD
Vemurafenib—Nausea—Etoposide—brain cancer	0.000223	0.00175	CcSEcCtD
Vemurafenib—CYP2D6—central nervous system—brain cancer	0.000221	0.00725	CbGeAlD
Vemurafenib—CYP2D6—cerebellum—brain cancer	0.000216	0.00709	CbGeAlD
Vemurafenib—CYP2D6—brain—brain cancer	0.000176	0.00576	CbGeAlD
Vemurafenib—BRAF—MAPK Signaling Pathway—TP53—brain cancer	8.5e-05	0.000575	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VAV1—brain cancer	8.49e-05	0.000574	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GLI2—brain cancer	8.47e-05	0.000572	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	8.26e-05	0.000558	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SHH—brain cancer	8.22e-05	0.000556	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ENO2—brain cancer	8.22e-05	0.000556	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CYP2C9—brain cancer	8.17e-05	0.000552	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—CCND1—brain cancer	8.09e-05	0.000547	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—EGFR—brain cancer	8.06e-05	0.000545	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	8.06e-05	0.000545	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—CTNNB1—brain cancer	8.02e-05	0.000542	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	7.98e-05	0.00054	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—STAT3—brain cancer	7.98e-05	0.000539	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GLI1—brain cancer	7.96e-05	0.000538	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—STAT3—brain cancer	7.94e-05	0.000537	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTCH2—brain cancer	7.73e-05	0.000523	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—EGFR—brain cancer	7.71e-05	0.000521	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—EGFR—brain cancer	7.71e-05	0.000521	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—VAV1—brain cancer	7.64e-05	0.000517	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	7.6e-05	0.000514	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—EGFR—brain cancer	7.59e-05	0.000513	CbGpPWpGaD
Vemurafenib—ALB—Platelet degranulation—VEGFA—brain cancer	7.59e-05	0.000513	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SUFU—brain cancer	7.55e-05	0.00051	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HES5—brain cancer	7.49e-05	0.000506	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HES1—brain cancer	7.44e-05	0.000503	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	7.44e-05	0.000503	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	7.44e-05	0.000503	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—STAT3—brain cancer	7.39e-05	0.0005	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—IL2—brain cancer	7.36e-05	0.000497	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—VAV1—brain cancer	7.34e-05	0.000496	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GFAP—brain cancer	7.28e-05	0.000492	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—IDH1—brain cancer	7.28e-05	0.000492	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—STAT3—brain cancer	7.28e-05	0.000492	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STRADA—brain cancer	7.27e-05	0.000491	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—EGFR—brain cancer	7.25e-05	0.00049	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—STAT3—brain cancer	7.23e-05	0.000489	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—brain cancer	7.23e-05	0.000489	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—EGFR—brain cancer	7.21e-05	0.000488	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—EGFR—brain cancer	7.21e-05	0.000488	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IDH1—brain cancer	7.2e-05	0.000486	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYP2C9—brain cancer	7.19e-05	0.000486	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—EGFR—brain cancer	7.18e-05	0.000485	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—MYC—brain cancer	7.16e-05	0.000484	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—EGFR—brain cancer	7.14e-05	0.000483	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—TP53—brain cancer	7.14e-05	0.000482	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IDH1—brain cancer	7.13e-05	0.000482	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—VEGFA—brain cancer	7.06e-05	0.000477	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	7.03e-05	0.000475	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—EGFR—brain cancer	7.01e-05	0.000474	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	6.97e-05	0.000471	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—BSG—brain cancer	6.95e-05	0.00047	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HEY1—brain cancer	6.9e-05	0.000467	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HEY1—brain cancer	6.82e-05	0.000461	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—DLL1—brain cancer	6.77e-05	0.000458	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HEY1—brain cancer	6.76e-05	0.000457	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—RELA—brain cancer	6.76e-05	0.000457	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—SHH—brain cancer	6.74e-05	0.000456	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—EGFR—brain cancer	6.72e-05	0.000454	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—EGFR—brain cancer	6.72e-05	0.000454	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—EGFR—brain cancer	6.72e-05	0.000454	CbGpPWpGaD
Vemurafenib—RAF1—Disease—DLL1—brain cancer	6.69e-05	0.000452	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TP53—brain cancer	6.69e-05	0.000452	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—EGFR—brain cancer	6.66e-05	0.00045	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—RELA—brain cancer	6.65e-05	0.000449	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—DLL1—brain cancer	6.63e-05	0.000448	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—EGFR—brain cancer	6.62e-05	0.000447	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—ERBB2—brain cancer	6.61e-05	0.000446	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—EGFR—brain cancer	6.6e-05	0.000446	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—EGFR—brain cancer	6.57e-05	0.000444	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—STAT3—brain cancer	6.55e-05	0.000443	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—TRPC6—brain cancer	6.5e-05	0.000439	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	6.47e-05	0.000437	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—SMO—brain cancer	6.39e-05	0.000432	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PTCH1—brain cancer	6.39e-05	0.000432	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—EGFR—brain cancer	6.35e-05	0.000429	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	6.32e-05	0.000427	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—PDGFRA—brain cancer	6.26e-05	0.000423	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—brain cancer	6.25e-05	0.000423	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—BSG—brain cancer	6.11e-05	0.000413	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TRPC6—brain cancer	6.1e-05	0.000412	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL2—brain cancer	6.09e-05	0.000412	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ABR—brain cancer	6.07e-05	0.00041	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PDGFRA—brain cancer	6.01e-05	0.000406	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—ERBB2—brain cancer	5.98e-05	0.000404	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—IDH1—brain cancer	5.97e-05	0.000404	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—brain cancer	5.95e-05	0.000402	CbGpPWpGaD
Vemurafenib—BRAF—Disease—VAV1—brain cancer	5.94e-05	0.000401	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—brain cancer	5.88e-05	0.000398	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GLI2—brain cancer	5.86e-05	0.000396	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SKP2—brain cancer	5.84e-05	0.000395	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—CDK4—brain cancer	5.84e-05	0.000394	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SHH—brain cancer	5.76e-05	0.000389	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	5.75e-05	0.000389	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SHH—brain cancer	5.69e-05	0.000384	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ENO2—brain cancer	5.69e-05	0.000384	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SHH—brain cancer	5.64e-05	0.000381	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ENO2—brain cancer	5.64e-05	0.000381	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	5.63e-05	0.00038	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TRPC6—brain cancer	5.55e-05	0.000375	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GLI1—brain cancer	5.51e-05	0.000372	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IRS2—brain cancer	5.49e-05	0.000371	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTCH1—brain cancer	5.46e-05	0.000369	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SMO—brain cancer	5.46e-05	0.000369	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—PIK3CG—brain cancer	5.39e-05	0.000364	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	5.31e-05	0.000359	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—TRPC6—brain cancer	5.28e-05	0.000357	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—IRS2—brain cancer	5.28e-05	0.000357	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—IDH1—brain cancer	5.26e-05	0.000355	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SUFU—brain cancer	5.22e-05	0.000353	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—STAT3—brain cancer	5.12e-05	0.000346	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HES1—brain cancer	5.11e-05	0.000345	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	5.09e-05	0.000344	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GFAP—brain cancer	5.04e-05	0.000341	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—STAT3—brain cancer	5.04e-05	0.000341	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—VAV1—brain cancer	4.87e-05	0.000329	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PDGFRA—brain cancer	4.86e-05	0.000329	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	4.86e-05	0.000329	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HEY1—brain cancer	4.78e-05	0.000323	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ENO2—brain cancer	4.72e-05	0.000319	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—DLL1—brain cancer	4.68e-05	0.000317	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—VEGFA—brain cancer	4.6e-05	0.000311	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—EGFR—brain cancer	4.58e-05	0.000309	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VAV1—brain cancer	4.57e-05	0.000309	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—VAV1—brain cancer	4.45e-05	0.000301	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP2C9—brain cancer	4.44e-05	0.0003	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOTCH2—brain cancer	4.36e-05	0.000295	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—RELA—brain cancer	4.29e-05	0.00029	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IRS2—brain cancer	4.27e-05	0.000289	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—ERBB2—brain cancer	4.27e-05	0.000288	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VAV1—brain cancer	4.16e-05	0.000281	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ENO2—brain cancer	4.15e-05	0.000281	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—EGFR—brain cancer	4.14e-05	0.00028	CbGpPWpGaD
Vemurafenib—RAF1—Disease—VAV1—brain cancer	4.11e-05	0.000278	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—VAV1—brain cancer	4.07e-05	0.000275	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SHH—brain cancer	3.98e-05	0.000269	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—IL2—brain cancer	3.96e-05	0.000268	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TRPC6—brain cancer	3.84e-05	0.00026	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IL2—brain cancer	3.79e-05	0.000256	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—RELA—brain cancer	3.79e-05	0.000256	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SMO—brain cancer	3.78e-05	0.000255	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTCH1—brain cancer	3.78e-05	0.000255	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—BSG—brain cancer	3.77e-05	0.000255	CbGpPWpGaD
Vemurafenib—BRAF—Disease—APC—brain cancer	3.77e-05	0.000255	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—ERBB2—brain cancer	3.77e-05	0.000255	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—CTNNB1—brain cancer	3.73e-05	0.000252	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP2C9—brain cancer	3.66e-05	0.000248	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PDGFRA—brain cancer	3.64e-05	0.000246	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—RELA—brain cancer	3.64e-05	0.000246	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ERBB2—brain cancer	3.62e-05	0.000245	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HES1—brain cancer	3.58e-05	0.000242	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HES1—brain cancer	3.53e-05	0.000239	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HES1—brain cancer	3.5e-05	0.000237	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PDGFRA—brain cancer	3.41e-05	0.00023	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VEGFA—brain cancer	3.37e-05	0.000227	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PDGFRA—brain cancer	3.37e-05	0.000227	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PDGFRA—brain cancer	3.34e-05	0.000225	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SPP1—brain cancer	3.31e-05	0.000223	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CTNNB1—brain cancer	3.3e-05	0.000223	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—VEGFA—brain cancer	3.29e-05	0.000222	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—STAT3—brain cancer	3.25e-05	0.00022	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—IDH1—brain cancer	3.24e-05	0.000219	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VEGFA—brain cancer	3.22e-05	0.000218	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IRS2—brain cancer	3.2e-05	0.000216	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—BSG—brain cancer	3.11e-05	0.00021	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2C9—brain cancer	3.1e-05	0.00021	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CG—brain cancer	3.09e-05	0.000209	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOTCH2—brain cancer	3.02e-05	0.000204	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IRS2—brain cancer	2.99e-05	0.000202	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EGFR—brain cancer	2.96e-05	0.0002	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IRS2—brain cancer	2.95e-05	0.0002	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IRS2—brain cancer	2.93e-05	0.000198	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ERBB2—brain cancer	2.93e-05	0.000198	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CG—brain cancer	2.9e-05	0.000196	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VAV1—brain cancer	2.88e-05	0.000195	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—IDH1—brain cancer	2.68e-05	0.000181	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CG—brain cancer	2.64e-05	0.000179	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—APC—brain cancer	2.64e-05	0.000179	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.64e-05	0.000178	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—BSG—brain cancer	2.64e-05	0.000178	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EGFR—brain cancer	2.61e-05	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Disease—APC—brain cancer	2.61e-05	0.000176	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—APC—brain cancer	2.59e-05	0.000175	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ENO2—brain cancer	2.56e-05	0.000173	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CTNNB1—brain cancer	2.56e-05	0.000173	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—brain cancer	2.51e-05	0.000169	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HES1—brain cancer	2.47e-05	0.000167	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—brain cancer	2.44e-05	0.000165	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2C9—brain cancer	2.39e-05	0.000162	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PDGFRA—brain cancer	2.36e-05	0.000159	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SPP1—brain cancer	2.29e-05	0.000155	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—IDH1—brain cancer	2.27e-05	0.000153	CbGpPWpGaD
Vemurafenib—BRAF—Disease—STAT3—brain cancer	2.23e-05	0.000151	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—RELA—brain cancer	2.21e-05	0.000149	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ERBB2—brain cancer	2.19e-05	0.000148	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2—brain cancer	2.18e-05	0.000147	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CG—brain cancer	2.17e-05	0.000146	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ENO2—brain cancer	2.12e-05	0.000143	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MYC—brain cancer	2.08e-05	0.00014	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IRS2—brain cancer	2.07e-05	0.00014	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RELA—brain cancer	2.06e-05	0.000139	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ERBB2—brain cancer	2.05e-05	0.000139	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2—brain cancer	2.04e-05	0.000138	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—BSG—brain cancer	2.04e-05	0.000138	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—brain cancer	2.03e-05	0.000137	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ERBB2—brain cancer	2.03e-05	0.000137	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ERBB2—brain cancer	2.01e-05	0.000136	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2—brain cancer	1.99e-05	0.000134	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CTNNB1—brain cancer	1.92e-05	0.00013	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CG—brain cancer	1.91e-05	0.000129	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2—brain cancer	1.86e-05	0.000126	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.85e-05	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APC—brain cancer	1.83e-05	0.000124	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CG—brain cancer	1.83e-05	0.000124	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCND1—brain cancer	1.81e-05	0.000122	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CTNNB1—brain cancer	1.79e-05	0.000121	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO2—brain cancer	1.79e-05	0.000121	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CTNNB1—brain cancer	1.77e-05	0.00012	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CTNNB1—brain cancer	1.76e-05	0.000119	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—IDH1—brain cancer	1.75e-05	0.000118	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—brain cancer	1.73e-05	0.000117	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—brain cancer	1.67e-05	0.000113	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—brain cancer	1.66e-05	0.000113	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—brain cancer	1.58e-05	0.000107	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—brain cancer	1.56e-05	0.000106	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—brain cancer	1.55e-05	0.000104	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—brain cancer	1.53e-05	0.000104	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—brain cancer	1.52e-05	0.000103	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—brain cancer	1.45e-05	9.82e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—brain cancer	1.44e-05	9.7e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RELA—brain cancer	1.43e-05	9.65e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—brain cancer	1.42e-05	9.62e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—brain cancer	1.42e-05	9.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB2—brain cancer	1.42e-05	9.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—brain cancer	1.4e-05	9.49e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—brain cancer	1.39e-05	9.41e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO2—brain cancer	1.38e-05	9.35e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—brain cancer	1.31e-05	8.86e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—brain cancer	1.29e-05	8.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—brain cancer	1.25e-05	8.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CTNNB1—brain cancer	1.24e-05	8.39e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—brain cancer	1.19e-05	8.07e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CG—brain cancer	1.18e-05	7.95e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—brain cancer	1.09e-05	7.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—brain cancer	1.08e-05	7.31e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—brain cancer	1.01e-05	6.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—brain cancer	9.83e-06	6.65e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CG—brain cancer	9.71e-06	6.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—brain cancer	8.26e-06	5.58e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CG—brain cancer	8.23e-06	5.56e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CG—brain cancer	6.35e-06	4.29e-05	CbGpPWpGaD
